PC-07 Clinical evaluation of three commercial PCR assays for the detection of macrolide resistance of Mycoplasma genitalium Chloé Le Roy 1 , Cécile Bébéar 1-2 , Sabine Pereyre 1-2 1 Univ. Bordeaux, INRA, USC EA 3671 Mycoplasmal and Chlamydial Infections in Humans, 2 Reference National Center of bacterial STI, Bordeaux, France. Bacteriology Department, Bordeaux University Hospital, Bordeaux, France. ➢ Clinical specimens : Prospective study between August 1 st and December 31 st 2018 at the National Reference Center for bacterial STI (Bordeaux, France) ➢ DNA extraction : MagNAPure 96 TM instrument (Roche Diagnostics). ➢ Detection : LightCycler 480 II instrument (Roche Diagnostics). 1
PC-07 RESULTS ➢ Agreement of M. genitalium detection with the ➢ Clinical performance of macrolide resistance detection on in-house real-time PCR assay 1 on 195 M. genitalium 154 M. genitalium- positive specimens. positive specimens. CI: confidence interval; IC: Internal control. CI: confidence interval; WT: wild-type. 2 1 Jensen et al. J. Clin. Microbiol. 2004.
PC-07 CONCLUSIONS ➢ Cost and handling of commercial kits ➢ The three kits do not discern between absence of mutation and absence of 23S rRNA gene amplification, leading to a risk of false macrolide susceptible results when the 23S rRNA gene is not amplified. ➢ The launch of three sensitive and specific commercial kits for the detection of M. genitalium and macrolide resistance will be useful to guide the choice of therapy. Le Roy C., Bébéar C. and Pereyre S. J Clin Microbiol. Clinical evaluation of three commercial PCR assays for the detection of macrolide resistance in Mycoplasma genitalium. 2019. in press. 3
Recommend
More recommend
